|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Oakwood Laboratories, LLC |
|---|---|
| Information provided by: | Oakwood Laboratories, LLC |
| ClinicalTrials.gov Identifier: | NCT00076531 |
Purpose
Phase III trial using an injectable for treatment of prostate cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostate Cancer |
Drug: Leuprolide Acetate for Injectable Suspension 22.5 mg |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Safety/Efficacy Study |
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Contacts and Locations
More Information
| Study ID Numbers: | OL-007 |
| Study First Received: | January 26, 2004 |
| Last Updated: | January 24, 2008 |
| ClinicalTrials.gov Identifier: | NCT00076531 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Prostate Cancer PSA Leuprolide |
|
Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents, Hormonal Antineoplastic Agents Physiological Effects of Drugs Urogenital Neoplasms Reproductive Control Agents Genital Diseases, Male |
Pharmacologic Actions Neoplasms Neoplasms by Site Leuprolide Therapeutic Uses Fertility Agents, Female Fertility Agents Prostatic Neoplasms |